➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Boehringer Ingelheim
Mallinckrodt
Colorcon
Medtronic

Last Updated: July 23, 2021

DrugPatentWatch Database Preview

SULFACETAMIDE SODIUM - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for sulfacetamide sodium and what is the scope of freedom to operate?

Sulfacetamide sodium is the generic ingredient in seventeen branded drugs marketed by Bausch, Fougera Pharms, Perrigo Co Tennessee, Taro, Allergan, Alcon, Schering, Pharmafair, Miza Pharms Usa, Akorn, Sola Barnes Hind, Novartis, Optopics, Alcon Pharms Ltd, Bausch And Lomb, and Sandoz Inc, and is included in thirty NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for sulfacetamide sodium. Six suppliers are listed for this compound.

Summary for SULFACETAMIDE SODIUM
Recent Clinical Trials for SULFACETAMIDE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityN/A

See all SULFACETAMIDE SODIUM clinical trials

Pharmacology for SULFACETAMIDE SODIUM
Medical Subject Heading (MeSH) Categories for SULFACETAMIDE SODIUM

US Patents and Regulatory Information for SULFACETAMIDE SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmafair SULFAIR FORTE sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 088385-001 Oct 13, 1983 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Miza Pharms Usa OCUSULF-10 sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 080660-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Alcon Pharms Ltd SULFACETAMIDE SODIUM sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 089068-001 May 5, 1987 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Bausch And Lomb SULTEN-10 sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 087818-001 Feb 3, 1983 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Akorn SODIUM SULFACETAMIDE sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 083021-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Schering SODIUM SULAMYD sulfacetamide sodium OINTMENT;OPHTHALMIC 005963-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Allergan BLEPH-10 sulfacetamide sodium OINTMENT;OPHTHALMIC 084015-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Boehringer Ingelheim
Mallinckrodt
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.